De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Galapagos Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Paul Stoffels

Algemeen directeur

€2.0m

Totale compensatie

Percentage CEO-salaris	38.0%
Dienstverband CEO	2.5yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.4yrs
Gemiddelde ambtstermijn bestuur	2.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Paul Stoffels's beloning veranderd ten opzichte van Galapagos's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	€32m
Mar 31 2024	n/a	n/a	€31m
Dec 31 2023	€2m	€750k	-€4m
Sep 30 2023	n/a	n/a	-€153m
Jun 30 2023	n/a	n/a	-€46m
Mar 31 2023	n/a	n/a	-€69m
Dec 31 2022	€1m	€563k	-€71m

Compensatie versus markt: De totale vergoeding ($USD 2.18M ) Paul } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 2.28M ).

Compensatie versus inkomsten: De vergoeding van Paul is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Paul Stoffels (62 yo)

2.5yrs

Tenure

€1,971,286

Compensatie

Dr. Paulus A. Stoffels, also known as Paul, Ph.D. M.D. is Chief Executive Officer of Galapagos NV since April 01, 2022 and also serves as its Chairman since April 26, 2022 and also serves as its Interim He...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Paulus Stoffels	CEO, Chairman	2.5yrs	€1.97m	geen gegevens
Thad Huston	Executive VP	1.3yrs	geen gegevens	geen gegevens
Sofie Van Gijsel	Head of Investor Relations	no data	geen gegevens	geen gegevens
Valeria Cnossen	Executive VP & General Counsel	2.8yrs	geen gegevens	geen gegevens
Marieke Vermeersch	Head of Corporate Communication	no data	geen gegevens	geen gegevens
Annelies Missotten	Executive VP & Chief Human Resources Officer	no data	geen gegevens	geen gegevens
Ellen Aar	Head of Development	no data	geen gegevens	geen gegevens
Philippe Alen	Senior VP & Head of Business Development	2.8yrs	geen gegevens	geen gegevens
Dirk De Naeyer	Head of Development Operations	no data	geen gegevens	geen gegevens
Alice Dietrich	Head of Medical Affairs	no data	geen gegevens	geen gegevens
Pierre Raboisson	Head of Small Molecules Discovery & Senior VP	2.3yrs	geen gegevens	geen gegevens
Patrik Ringblom	Head of Strategy & US Lead	less than a year	geen gegevens	geen gegevens

2.4yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0JXZ wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Paulus Stoffels	CEO, Chairman	2.5yrs	€1.97m	geen gegevens
Simon Sturge	Independent Non-Executive Director	1.1yrs	€32.37k	0.00027% € 4.6k
Jerome Contamine	Lead Independent Non-Executive Director	2.5yrs	€150.00k	0.0015% € 26.2k
Andrew Dickinson	Non-Executive Non-Independent Director	less than a year	geen gegevens	geen gegevens
Linda Higgins	Non-Executive Non-Independent Director	5yrs	geen gegevens	geen gegevens
Susanne Schaffert	Non-Executive Independent Director	1.3yrs	€59.85k	0.00055% € 9.4k
Peter Guenter	Independent Non-Executive Director	5.5yrs	€115.00k	0.0030% € 51.7k
Elisabeth Svanberg	Independent Non-Executive Director	4.5yrs	€138.75k	0.0029% € 49.0k
Daniel Baker	Non-Executive Independent Director	2.5yrs	€117.36k	0.0015% € 25.9k

2.5yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0JXZ wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.5 jaar), wat duidt op een nieuw bestuur.

Galapagos Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Galapagos NV Announces Board Changes

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

High number of new directors

Galapagos NV Announces Board Changes

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Galapagos NV Announces Director Changes

Recent updates

Investor sentiment improves as stock rises 16%

Galapagos Announces FDA Clearance of IND Application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in Relapsed/Refractory Non-Hodgkin Lymphoma

Second quarter 2024 earnings released

Galapagos NV to Report Fiscal Year 2024 Results on Feb 12, 2025

First quarter 2024 earnings released: EPS: €0.36 (vs €0.35 in 1Q 2023)

Full year 2023 earnings released: €0.061 loss per share (vs €1.09 loss in FY 2022)

Galapagos NV Announces Board Changes

Full year 2023 earnings released: €0.06 loss per share (vs €3.32 loss in FY 2022)

Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024

Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG).

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301

Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101

Galapagos NV to Report First Half, 2024 Results on Aug 01, 2024

Third quarter 2023 earnings released: EPS: €0.39 (vs €0.33 in 3Q 2022)

High number of new directors

Galapagos NV Announces Board Changes

Galapagos NV to Report Q4, 2023 Results on Mar 28, 2024

Galapagos NV Announces Start of Phase 2 Study with Selective Tyk2 Inhibitor, GLPG3667, in Patients with Active Systemic Lupus Erythematosus

New major risk - Revenue and earnings growth

Galapagos NV Revises Sales Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: €0.078 (vs €0.29 loss in 2Q 2022)

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Galapagos NV Announces Director Changes

Galapagos to Showcase CAR-T Point-Of-Care Manufacturing and Initial Phase 1/2 CLL Data with CD19 CAR-T Candidate, GLPG5201, at the EHA 2023 Congress

First quarter 2023 earnings released: EPS: €0.35 (vs €0.20 loss in 1Q 2022)

Full year 2022 earnings released: €3.32 loss per share (vs €1.92 loss in FY 2021)

Full year 2022 earnings released: €3.32 loss per share (vs €1.92 loss in FY 2021)

Galapagos NV Announces Topline Results from Phase 3 DIVERSITY Trial of Filgotinib in Crohn’s Disease

Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023

Galapagos and CellPoint Presented Encouraging Initial Data AtASH 2022 for GLPG5101, a CD19 CAR-T Candidate Manufactured At Point-Of-Care

Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyseleca® Following Extensive Safety Review of all JAK Inhibitors

Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos NV to Report Fiscal Year 2022 Final Results on Mar 23, 2023

Third quarter 2022 earnings released: EPS: €0.30 (vs €0.99 loss in 3Q 2021)

Galapagos NV to Report Q1, 2023 Results on May 04, 2023

Galapagos Receives Positive CHMP Opinion for Jyseleca® European Label Update Based on Testicular Function Safety Data from MANTA/RAy Studies

Galapagos NV announced that it has received €3.07625 million in funding

Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022

Second quarter 2022 earnings released: €0.29 loss per share (vs €0.98 loss in 2Q 2021)

Galapagos NV (ENXTAM:GLPG) entered into a definitive agreement to acquire Abound Bio, Inc. for $14 million.

Galapagos NV announced that it expects to receive €1.459507 million in funding

High number of new directors

First quarter 2022 earnings released: €0.20 loss per share (vs €0.20 loss in 1Q 2021)

Galapagos NV to Report Q3, 2022 Results on Nov 03, 2022

Galapagos NV Announces Executive Appointments

Galapagos NV Announces Approval of Additional Indication Based on Phase 2B/3 SELECTION Study in Patients with Moderate-To-Severe Ulcerative Colitis

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Galapagos Provides Further Insights into the Treatment of Ulcerative Colitis At the European Crohn’s and Colitis Organization Annual Congress

Galapagos NV Announces Authorization of Medicines and Healthcare Products Regulatory Agency for Jyseleca (Filgotinib), as New Treatment for Ulcerative Colitis in Great Britain

Galapagos Nv Completes Patient Recruitment for Mangrove Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Third quarter 2021 earnings released: €0.64 loss per share (vs €1.25 loss in 3Q 2020)

Galapagos Announces Positive CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Second quarter 2021 earnings released: €0.98 loss per share (vs €1.80 loss in 2Q 2020)

Galapagos NV Demonstrates Early Clinical Activity with SIK2/3 Inhibition in Inflammation

Galapagos NV Announces That Primary and Secondary Endpoint Results from the Phase 3 SELECTIONinduction

Galapagos NV to Present Data on Rheumatoid Arthritis At the Upcoming European League Against Rheumatism (EULAR) Congress

Galapagos Announces First Patient Enrolled in FILOSOPHY Study to Advance Understanding of Jyseleca (Filgotinib) Effectiveness and Safety in A Real-World Setting

Galapagos Reports Primary Endpoint for the Ongoing Filgotinib MANTA and MANTA-RAy Safety Studies

Revenue beats expectations

Galapagos NV to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF

New 90-day low: €73.62

Galapagos NV to Report Fiscal Year 2021 Results on Feb 24, 2022

NICE Recommends Galapagos Jyseleca (Filgotinib) on NHS in Decision for Rheumatoid Arthritis

Selvita S.A. (WSE:SLV) completed the acquisition of Fidelta D.O.O. from Galapagos NV (ENXTAM:GLPG).

Gilead Sciences, Inc. and Galapagos NV Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

New 90-day low: €98.00

Galapagos NV Reports Positive Topline Results with GLPG1205 in IPF Patients in PINTA Proof-of-Concept Trial